Status: Recruiting
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.
Participants needed: 183
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Stryker NeurovascularUpdated: Apr 8, 2026Locations: 10
Eligibility criteria
Age is ≥18 and ≤80 years at the time of consent [+5]
Has an extradural target aneurysm [+24]